Patrick J. Engelberts

Patrick J. Engelberts

Auto-generated profile, based on publicly available information

Patrick J. Engelberts

Genmab (Netherlands) 1 Utrecht

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JMJim Middelburg
Jim Middelburg
KKKristel Kemper
Kristel Kemper
PEPatrick Engelberts
Patrick Engelberts
ALAran F. Labrijn
Aran F. Labrijn
JSJanine Schuurman
Janine Schuurman
THThorbald van Hall
Thorbald van Hall
Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers. Furthermore, we describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses.

15 December 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
PEPatrick J. Engelberts
Patrick J. Engelberts
MVMarleen Voorhorst
Marleen Voorhorst
JSJanine Schuurman
Janine Schuurman
TMTom van Meerten
Tom van Meerten
JBJoost M. Bakker
Joost M. Bakker
FBFrank J. Beurskens
Frank J. Beurskens
Human IgG1 type I CD20 Abs, such as rituximab and ofatumumab (OFA), efficiently induce complement-dependent cytotoxicity (CDC) of CD20+ B cells by binding of C1 to hexamerized Fc domains. Unexpectedly, we found that type I CD20 Ab F(ab′)2 fragments, as well as C1q-binding–deficient IgG mutants, retained an ability to induce CDC, albeit with lower efficiency than for whole or unmodified IgG. Experiments using human serum depleted of specific complement components demonstrated that the observed lytic activity, which we termed “accessory CDC,” remained to be dependent on C1 and the classical pathway. We hypothesized that CD20 Ab-induced clustering of the IgM or IgG BCR was involved in accessory CDC. Indeed, accessory CDC was consistently observed in B cell lines expressing an IgM BCR and in some cell lines expressing an IgG BCR, but it was absent in BCR− B cell lines. A direct relationship between BCR expression and accessory CDC was established by transfecting the BCR into CD20+ cells: OFA-F(ab′)2 fragments were able to induce CDC in the CD20+BCR+ cell population, but not in the CD20+BCR− population. Importantly, OFA-F(ab′)2 fragments were able to induce CDC ex vivo in malignant B cells isolated from patients with mantle cell lymphoma and Waldenström macroglobulinemia. In summary, accessory CDC represents a novel effector mechanism that is dependent on type I CD20 Ab–induced BCR clustering. Accessory CDC may contribute to the excellent capacity of type I CD20 Abs to induce CDC, and thereby to the antitumor activity of such Abs in the clinic.

15 April 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PEPatrick J Engelberts
Patrick J Engelberts
EBEsther C W Breij
Esther C W Breij
TVT Valerius
T Valerius
JSJanine Schuurman
Janine Schuurman
PPPaul W H I Parren
Paul W H I Parren
FBF J Beurskens
F J Beurskens

30 June 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
LKLouise A. Koopman
Louise A. Koopman
FAFarshid Alemdehy
Farshid Alemdehy
SPStefanie A.H. de Poot
Stefanie A.H. de Poot
MPMadelon Paauwe
Madelon Paauwe
WWWenyi Wang
Wenyi Wang
EBEsther C.W. Breij
Esther C.W. Breij
The immune checkpoint protein B7H4 is overexpressed in tumors compared to normal tissues, making it an attractive target for cancer immunotherapy. Here, we compare two B7H4-targeting CD3 bispecific antibodies (bsAbs) with different CD3 affinities across in vitro and in vivo characterization studies. In vitro, the CD3xB7H4 bsAb variant with higher CD3 affinity showed greater potency for tumor cell killing and cytokine secretion than the lower affinity variant. In nonclinical toxicology assessments in cynomolgus monkeys, the CD3xB7H4 bsAb variant with lower CD3 affinity induced less cytokine secretion and was tolerated at a higher maximum plasma concentration. Both CD3xB7H4 bsAbs demonstrated antitumor activity in vivo in an ovarian cancer patient-derived xenograft (PDX) mouse model and ex vivo in dissociated primary human ovarian tumor samples. These results demonstrate that increased CD3 affinity enhances cytotoxic potency but results in cytokine secretion at lower antibody concentrations in vitro and in vivo, highlighting an important design trade-off in CD3 bsAb development. The therapeutic potential of CD3xB7H4 bsAbs, particularly in relation to CD3 affinity, warrants further investigation in the clinic.